Page last updated: 2024-08-24

imiquimod and Insulin Resistance

imiquimod has been researched along with Insulin Resistance in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chen, P; Li, X; Shao, Z; Xu, X	1

Other Studies

1 other study(ies) available for imiquimod and Insulin Resistance

Article	Year
DPP-4 inhibitor linagliptin ameliorates imiquimod-induced psoriasis-like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF-κB inflammatory pathway. Drug development research, 2022, Volume: 83, Issue:6 Topics: Animals; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Imiquimod; Insulin Resistance; Interleukin-23; Linagliptin; Mice; NF-kappa B; Psoriasis; Tumor Necrosis Factor-alpha	2022

Article

Year

DPP-4 inhibitor linagliptin ameliorates imiquimod-induced psoriasis-like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF-κB inflammatory pathway.

Drug development research, 2022, Volume: 83, Issue:6

Topics: Animals; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Imiquimod; Insulin Resistance; Interleukin-23; Linagliptin; Mice; NF-kappa B; Psoriasis; Tumor Necrosis Factor-alpha

2022